AVE9633

DB06318

biotech investigational

Deskripsi

AVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

685 Data
Eliglustat The metabolism of Eliglustat can be decreased when combined with AVE9633.
Ibrutinib The metabolism of Ibrutinib can be decreased when combined with AVE9633.
Alfentanil The serum concentration of Alfentanil can be increased when it is combined with AVE9633.
Buspirone The metabolism of Buspirone can be decreased when combined with AVE9633.
Carbamazepine The metabolism of Carbamazepine can be decreased when combined with AVE9633.
Cisapride The serum concentration of Cisapride can be increased when it is combined with AVE9633.
Disopyramide AVE9633 may increase the QTc-prolonging activities of Disopyramide.
Estazolam The serum concentration of Estazolam can be increased when it is combined with AVE9633.
Quinine The serum concentration of Quinine can be increased when it is combined with AVE9633.
Quinidine The serum concentration of Quinidine can be increased when it is combined with AVE9633.
Repaglinide The serum concentration of Repaglinide can be increased when it is combined with AVE9633.
Sirolimus The metabolism of Sirolimus can be decreased when combined with AVE9633.
Temsirolimus The metabolism of Temsirolimus can be decreased when combined with AVE9633.
Terfenadine The serum concentration of Terfenadine can be increased when it is combined with AVE9633.
Triazolam The serum concentration of Triazolam can be increased when it is combined with AVE9633.
Cilostazol The metabolism of Cilostazol can be decreased when combined with AVE9633.
Colchicine The metabolism of Colchicine can be decreased when combined with AVE9633.
Iloperidone The metabolism of Iloperidone can be decreased when combined with AVE9633.
Retapamulin The metabolism of Retapamulin can be decreased when combined with AVE9633.
Tofacitinib The metabolism of Tofacitinib can be decreased when combined with AVE9633.
Vardenafil The metabolism of Vardenafil can be decreased when combined with AVE9633.
Eszopiclone The metabolism of Eszopiclone can be decreased when combined with AVE9633.
Zopiclone The metabolism of Zopiclone can be decreased when combined with AVE9633.
Lovastatin The metabolism of Lovastatin can be decreased when combined with AVE9633.
Alfuzosin The metabolism of Alfuzosin can be decreased when combined with AVE9633.
Alprazolam The serum concentration of Alprazolam can be increased when it is combined with AVE9633.
Warfarin The serum concentration of Warfarin can be increased when it is combined with AVE9633.
Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with AVE9633.
(R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with AVE9633.
R,S-Warfarin alcohol The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with AVE9633.
S,R-Warfarin alcohol The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with AVE9633.
(S)-Warfarin The serum concentration of (S)-Warfarin can be increased when it is combined with AVE9633.
Midazolam The serum concentration of Midazolam can be increased when it is combined with AVE9633.
Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with AVE9633.
Telaprevir The serum concentration of Telaprevir can be increased when it is combined with AVE9633.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of AVE9633.
Estrone Estrone may increase the thrombogenic activities of AVE9633.
Dienestrol Dienestrol may increase the thrombogenic activities of AVE9633.
Estriol Estriol may increase the thrombogenic activities of AVE9633.
Quinestrol Quinestrol may increase the thrombogenic activities of AVE9633.
Hexestrol Hexestrol may increase the thrombogenic activities of AVE9633.
Tibolone Tibolone may increase the thrombogenic activities of AVE9633.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of AVE9633.
Zeranol Zeranol may increase the thrombogenic activities of AVE9633.
Equol Equol may increase the thrombogenic activities of AVE9633.
Promestriene Promestriene may increase the thrombogenic activities of AVE9633.
Methallenestril Methallenestril may increase the thrombogenic activities of AVE9633.
Epimestrol Epimestrol may increase the thrombogenic activities of AVE9633.
Moxestrol Moxestrol may increase the thrombogenic activities of AVE9633.
Biochanin A Biochanin A may increase the thrombogenic activities of AVE9633.
Formononetin Formononetin may increase the thrombogenic activities of AVE9633.
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of AVE9633.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of AVE9633.
Estradiol Estradiol may increase the thrombogenic activities of AVE9633.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of AVE9633.
Mestranol Mestranol may increase the thrombogenic activities of AVE9633.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of AVE9633.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of AVE9633.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of AVE9633.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of AVE9633.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of AVE9633.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of AVE9633.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of AVE9633.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of AVE9633.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with AVE9633.
Vintafolide The serum concentration of Vintafolide can be increased when it is combined with AVE9633.
Vincamine The serum concentration of Vincamine can be increased when it is combined with AVE9633.
Acetyldigitoxin The serum concentration of Acetyldigitoxin can be increased when it is combined with AVE9633.
Deslanoside The serum concentration of Deslanoside can be increased when it is combined with AVE9633.
Ouabain The serum concentration of Ouabain can be increased when it is combined with AVE9633.
Oleandrin The serum concentration of Oleandrin can be increased when it is combined with AVE9633.
Cymarin The serum concentration of Cymarin can be increased when it is combined with AVE9633.
Proscillaridin The serum concentration of Proscillaridin can be increased when it is combined with AVE9633.
Metildigoxin The serum concentration of Metildigoxin can be increased when it is combined with AVE9633.
Lanatoside C The serum concentration of Lanatoside C can be increased when it is combined with AVE9633.
Gitoformate The serum concentration of Gitoformate can be increased when it is combined with AVE9633.
Acetyldigoxin The serum concentration of Acetyldigoxin can be increased when it is combined with AVE9633.
Peruvoside The serum concentration of Peruvoside can be increased when it is combined with AVE9633.
Cyclosporine The metabolism of Cyclosporine can be decreased when combined with AVE9633.
Dicoumarol The serum concentration of Dicoumarol can be increased when it is combined with AVE9633.
Phenindione The serum concentration of Phenindione can be increased when it is combined with AVE9633.
Coumarin The serum concentration of Coumarin can be increased when it is combined with AVE9633.
Tioclomarol The serum concentration of Tioclomarol can be increased when it is combined with AVE9633.
Ethyl biscoumacetate The serum concentration of Ethyl biscoumacetate can be increased when it is combined with AVE9633.
Diphenadione The serum concentration of Diphenadione can be increased when it is combined with AVE9633.
4-hydroxycoumarin The serum concentration of 4-hydroxycoumarin can be increased when it is combined with AVE9633.
Fluindione The serum concentration of Fluindione can be increased when it is combined with AVE9633.
Clorindione The serum concentration of Clorindione can be increased when it is combined with AVE9633.
Oxtriphylline The metabolism of Oxtriphylline can be decreased when combined with AVE9633.
Doxofylline The metabolism of Doxofylline can be decreased when combined with AVE9633.
Bamifylline The metabolism of Bamifylline can be decreased when combined with AVE9633.
Acefylline The metabolism of Acefylline can be decreased when combined with AVE9633.
Bufylline The metabolism of Bufylline can be decreased when combined with AVE9633.
Fenethylline The metabolism of Fenethylline can be decreased when combined with AVE9633.
Proxyphylline The metabolism of Proxyphylline can be decreased when combined with AVE9633.
Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with AVE9633.
Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with AVE9633.
8-azaguanine The metabolism of 8-azaguanine can be decreased when combined with AVE9633.
7,9-Dimethylguanine The metabolism of 7,9-Dimethylguanine can be decreased when combined with AVE9633.
Xanthine The metabolism of Xanthine can be decreased when combined with AVE9633.

Target Protein

Myeloid cell surface antigen CD33 CD33

Referensi & Sumber

Link

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul